Biomatics Capital Partners, L.P. 3
3 · Verve Therapeutics, Inc. · Filed Jun 16, 2021
Insider Transaction Report
Form 3
Biomatics Capital Partners, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (88,653 underlying)Series A Preferred Stock
→ Common Stock (1,535,077 underlying)Series A-2 Preferred Stock
→ Common Stock (973,734 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's preferred stock is convertible into common stock on an approximately 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
- [F2]These shares are held by Biomatics Capital Partners, LP ("Biomatics LP"). Biomatics Capital Management, L.L.C. ("Biomatics GP") is the general partner of Biomatics LP. Julie Sunderland and Boris Nikolic ( the "Managing Members") are the managing members of Biomatics GP. Each of the Managing Members may be deemed to share voting and dispositive power over these shares. Each of the Managing Members and Biomatics GP disclaim beneficial ownership of these shares and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.